Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,508 JPY | +1.89% | +3.57% | +6.12% |
Sales 2024 * | 35.22B 227M | Sales 2025 * | 38.94B 251M | Capitalization | 132B 855M |
---|---|---|---|---|---|
Net income 2024 * | 951M 6.14M | Net income 2025 * | 3.47B 22.41M | EV / Sales 2024 * | 3.45 x |
Net cash position 2024 * | 10.81B 69.82M | Net cash position 2025 * | 12.21B 78.83M | EV / Sales 2025 * | 3.09 x |
P/E ratio 2024 * |
66.1
x | P/E ratio 2025 * |
26.1
x | Employees | 350 |
Yield 2024 * |
-
| Yield 2025 * |
0.05% | Free-Float | 88.87% |
Latest transcript on Nxera Pharma Co., Ltd.
1 day | +1.89% | ||
1 week | +3.08% | ||
Current month | -9.27% | ||
1 month | -4.44% | ||
3 months | +3.36% | ||
6 months | +11.79% | ||
Current year | +6.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 17-09-19 |
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Director of Finance/CFO | - | 22-03-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 19-03-26 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 20-03-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.92% | 24 M€ | -11.55% | ||
1.17% | 16 M€ | -6.73% | ||
0.55% | 15 M€ | +7.30% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1,508 | +1.89% | 708 600 |
24-04-23 | 1,480 | +0.89% | 584,900 |
24-04-22 | 1,467 | +1.17% | 602,200 |
24-04-19 | 1,450 | -4.04% | 1,064,700 |
24-04-18 | 1,511 | +3.28% | 762,900 |
Delayed Quote Japan Exchange, April 24, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.12% | 855M | |
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.25% | 24.72B | |
-4.52% | 17.47B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+1.65% | 8.44B |
- Stock Market
- Equities
- 4565 Stock